BIO-Europe Spring® 2017: Celyad VP talks IP issues, development timelines for CAR-T therapies

April 13, 2017
Georges Rawadi, VP of business development and intellectual property at Celyad, discusses the company's CAR-T pipeline, recently resolved IP issues and the firm's strategy for future clinical development. At the recent BIO-Europe Spring partnering meeting in Barcelona, Rawadi told Scrip more about how Celyad's technology will compete with other treatments coming through the immuno-oncology development pipeline and the next big milestones for the business.
Previous Video
BIO-Europe Spring® 2017: Noxxon CEO discusses partners and cancer combinations
BIO-Europe Spring® 2017: Noxxon CEO discusses partners and cancer combinations

Noxxon CEO Aram Mangasarian talks to Scrip about development plans for the company's lead compound NOX-A12,...

Next Video
BIO-Europe Spring® 2017: TxCell plans first-in-man trial of regulatory T cells
BIO-Europe Spring® 2017: TxCell plans first-in-man trial of regulatory T cells

Having completed a Phase I/IIa study of Ovasave, a drug candidate from its first generation non-modified an...